Study Evaluating Toro 88 Super Bore Aspiration Catheter for Acute Ischemic Stroke

Inclusion Criteria: * Patients aged ≥ 18 and ≤ 90 years at the time of consent * Presenting with an acute ischaemic stroke for which symptoms (or last time seen as normal) are \< 24h * With occlusion of the ICA / the M1 segment of the MCA / a vertebral artery diameter ≥3.5mm / the basilar artery, defined by eTICI≤1 * Requiring endovascular treatment (mechanical thrombectomy) with or without intravenous thrombolysis * For whom the experimental device is the first-line treatment * Without pre-existing disability (mRS ≤3 and 6≤ NIHSS ≤30 before stroke) * Informed consent signed : * By the patient * Or consent by a family member/trusted support person if the patient's condition does not allow them to express their consent in writing (L1111-6) Exclusion Criteria: * Arterial dissection * Suspicion of vasculitis * Suspected intracranial stenosis near the occlusion site * Concomitant intracranial haemorrhage * Known coagulation disorder * Known coagulopathy * Known platelet count \<50,000/μL * Significant mass effect with midline shift * Suspicion or evidence of aortic dissection, septic embolus, or bacterial endocarditis * INR ≥ 3.0 * APTT ≥ 2 times normal * Systolic blood pressure \> 185 mmHg and/or diastolic blood pressure \< 110 mmHg * Blood glucose \< 50 mg/dL or \>400 mg/dL according to the last measurement taken before the procedure * Known allergy to contrast media * Occluded arteries in more than one large vascular territory (at least two of the left and right internal carotid arteries or the territory of a carotid artery and an artery of the vertebrobasilar system). * Pregnant or breast-feeding women (urine or serum pregnancy test negative at inclusion). * Adults under legal protection (L1121-8) * Persons deprived of their liberty by judicial or administrative decision, persons under psychiatric care under articles L3212-1 and L3123-1 and persons admitted to a health or social establishment for purposes other than research (L1121-6). * Participation in other interventional clinical research